Replies to post #50721 on Biotech Values

[walldiver]

I own JAV but no longer own REGN. There are always going to be trading opportunities if you time it right, but I think that clinically, REGN has a tough uphill climb ahead of it...so I prefer to invest my money elsewhere.

[DewDiligence]

REGN – I think the AMD program will end up failing even if it nominally succeeds. In other words, it is aiming too low.

Now that $5/dose Avastin is available and there is no longer any semblance of physician liability for using it, a new drug that is merely as good as Lucentis/Avastin is likely going to be a commercial dud.

What Bayer and REGN need to show to make VEGF-Trap-eye a commercial success is clear superiority to Lucentis on the metric of improved vision (a gain of 3+ lines relative to baseline). However, the phase-3 trial just announced is inadequately powered to show this, IMO.